Alnylam Pharma (ALNY) Tops Q1 EPS by 37c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $301.67 +0.21%
Revenue Growth %: +70.6%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
CRMT, FOMI, FLES, More
Revenue Growth %: +70.6%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
CRMT, FOMI, FLES, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.52), $0.37 better than the analyst estimate of ($1.89). Revenue for the quarter came in at $99.5 million versus the consensus estimate of $91.56 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $470 at H.C. Wainwright
- Goldman Sachs Downgrades SkyWest (SKYW) to Neutral
- Whirlpool to close Mexico plant, expects $165M restructuring cost
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
